Fundraising Fox
Renerva
Pittsburgh, US · Founded 2017 · Delaware LLC · 1 known investors
Find your way into Renerva
Sign up to see every warm intro you have to Renerva
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Renerva team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Renerva develops implantable medical devices to treat peripheral nerve injuries. The company was founded from academic research at the University of Pittsburgh and Cornell University.
Founders & leadership
LS
Lorenzo SolettiCo-Founder and CEOLorenzo Soletti is LLC Manager at Renerva, which develops implantable medical devices for peripheral nerve injury treatment. He brings over 15 years of professional experience in medical technology and entrepreneurship.
WA
William A SekkelBoard MemberWilliam A Sekkel previously held executive roles at Ingersoll Rand, including President of Latin America operations for the Trane Commercial and Thermo King divisions. He is now LLC Manager of Renerva, an implantable medical device company focused on treating peripheral nerve injuries.
PD
Peter DeComoLLC Manager
JC
J. Christopher FlahertyExecutive Vice President for Intellectual Property
PA
Paul A GardnerChief Medical Officer
Board
JC
Jonathan CheethamChairman of the Scientific Advisory Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 3 rounds · 2018–2025
▶$324.8KraisedSep 2025 · 35 investors · Other Health CareRule 506(b)
▶$324.8KraisedSep 2025 · 35 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter DeComoDirector
- Bryan N. BrownExecutive Officer
- William A SekkelDirector
- Lorenzo SolettiExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $324.8K
- Proceeds to insiders
- $53K
- First sale
- Sep 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$335KraisedAug 2024 · 14 investors · Other Health CareRule 506(b)
▶$335KraisedAug 2024 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lorenzo SolettiExecutive Officer, Director
- Bryan N. BrownExecutive Officer
- William A SekkelDirector
- Peter DeComoDirector
- Offering amount
- $1.5M
- Amount sold
- $335K
- Proceeds to insiders
- $75K
- First sale
- Jul 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$617.3KraisedAug 2018 · 12 investors · Other Health CareRule 506(b)
▶$617.3KraisedAug 2018 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- J. Christopher FlahertyExecutive Officer
- Bryan N. BrownExecutive Officer
- Lorenzo SolettiExecutive Officer, Director
- Paul A GardnerExecutive Officer
- Jonathan CheethamExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $617.3K
- Minimum investment
- $25K
- Proceeds to insiders
- $200K
- First sale
- Jun 2018
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Minerva BiotechnologiesMinerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
Minerva NeurosciencesMinerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders. It focuses on designing clinical trials with endpoints tied to patient benefit.
Minerva SurgicalMinerva Surgical is a women's health medical device company focused on technologies for conditions such as heavy menstrual bleeding, offering alternatives to hysterectomy. It provides support to clinical teams using its products.
LeadIQLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.
Companies working in the same space as Renerva.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $495K |
| National Science Foundation | Phase II | 2022 | $996.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $274.3K |
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Renerva do?
- Renerva develops implantable medical devices to treat peripheral nerve injuries. The company was founded from academic research at the University of Pittsburgh and Cornell University.
- Who are Renerva's investors?
- Renerva's investors include Cowtown Angels.
- How much funding has Renerva raised?
- Renerva has disclosed $1.3M raised across 3 rounds.
- Where is Renerva headquartered?
- Renerva is headquartered in Pittsburgh, US.